Quinoline-Amide Isoindolinone Derivatives for CRBN Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing thalidomide derivatives used for treating leprosy, chronic graft-versus-host disease, inflammatory diseases, and cancer have significant side effects, necessitating the development of compounds that retain their therapeutic benefits while minimizing these drawbacks.
Innovation Solution
Development of quinoline-substituted isoindolinone derivatives with a glutarimide moiety, represented by Chemical Formula 1, which bind to the CRBN protein to induce degradation of Ikaros/Aiolos and GSPT1, offering potential therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thalidomide and its derivatives are used to treat leprosy, chronic graft-versus-host disease, inflammatory diseases, and cancer, then therapeutic benefits are achieved, but serious side effects including birth defects occur
Solution Approach 1:
The patent divides the thalidomide molecule into distinct functional segments: the glutarimide ring (which binds to CRBN) and the substituted phenylisoxazole portion. By modifying the phenylisoxazole segment with specific substituents (R1-R6 groups), the invention creates derivatives that maintain CRBN binding capability while reducing teratogenic effects. This segmentation allows independent optimization of therapeutic activity and safety profile.
Solution Approach 2:
The patent applies local quality by introducing specific substituents at defined positions (R1-R6) on the phenylisoxazole ring. Each substituent position can be independently modified with different chemical groups to fine-tune the molecule's properties. This localized modification approach enables preservation of essential CRBN binding interactions while altering regions associated with harmful effects.
2Object-affected harmful factors
If thalidomide derivatives are developed to eliminate side effects, then safety is improved, but maintaining therapeutic activity becomes challenging
Solution Approach 1:
The patent systematically varies chemical parameters including substituent types (halogen, alkyl, alkoxy, nitro, cyano, carboxyl groups), their positions on the phenylisoxazole ring, and the presence/absence of specific functional groups. These parameter changes are designed to modulate CRBN binding affinity and selectivity while reducing off-target effects. The structured approach allows identification of optimal parameter combinations that balance safety and efficacy.
Data Source
Figure 1~2
AI summary
The present invention relates to: an isoindolinone derivative compound having a glutarimide mother nucleus in which quinoline is substituted; and application thereof, and, more specifically, to an isoindolinone derivative compound having a glutarimide mother nucleus, in which quinoline is substituted, with a thalidomide analog structure. A compound of chemical formula 1, according to the present invention, specifically binds to a CRBN protein and is involved in functions thereof. Therefore, the compound of the present invention can be effectively used in the prevention or treatment of leprosy, chronic graft versus host disease, inflammatory diseases or cancer, which are caused by activity of the CRBN protein.